AAPL VS PTCT Stock Comparison
Performance
AAPL100/100
100/100
AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.
PTCT10/100
10/100
PTCT returned -45.44% in the last 12 months. Based on SPY's performance of -13.61%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
AAPL78/100
78/100
38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.
PTCT56/100
56/100
8 analysts offer 12-month price targets for PTCT. Together, they have an average target of 47.25, the most optimistic target put PTCT at 63 within 12-months and the most pessimistic has PTCT at 35.
Sentiment
AAPL70/100
70/100
AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.
PTCT
"Sentiment" not found for PTCT
Technicals
AAPL18/100
18/100
AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.
PTCT50/100
50/100
PTCT receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
AAPL100/100
100/100
AAPL has missed earnings 1 times in the last 20 quarters.
PTCT10/100
10/100
PTCT has missed earnings 14 times in the last 20 quarters.
Profit
AAPL76/100
76/100
Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.
PTCT10/100
10/100
Out of the last 20 quarters, PTCT has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
AAPL45/100
45/100
AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
PTCT48/100
48/100
PTCT has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
Dividend
AAPL50/100
50/100
AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.
PTCT
"Dividend" not found for PTCT
All score calculations are broken down here to help you make more informed investing decisions
Apple Inc. Summary
Nasdaq / AAPL
Technology
Consumer Electronics
Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.
PTC Therapeutics, Inc. Summary
Nasdaq / PTCT
Healthcare
Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare AAPL to other companies in the same or a similar industry.